Dimethyltryptamine is under clinical development by Viridia Life Sciences and currently in Phase I for Treatment Resistant Depression. According to GlobalData, Phase I drugs for Treatment Resistant Depression have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dimethyltryptamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dimethyltryptamine overview
Dimethyltryptamine (DMT) is under development for the treatment of depression. DMT is an active ingredient in Ayahuasca and acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A). It is administered as buccal transmucosal film and also through intravenous route.
See Also:
Viridia Life Sciences overview
Viridia Life Sciences (Viridia Life) is a biotechnology company that engaged in developing a digital therapeutic including cognitive behavioral therapy, group therapy, and patient monitoring post dosing. The company is headquartered in New Castle, the US.
For a complete picture of Dimethyltryptamine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
